

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

Comparison the effect of magnesium sulfate and nifedipine in the successful treatment of preterm labor

Protocol summary

Summary

This is a randomized clinical trial. The aim of this study was to compare the effect of nifedipine and magnesium sulfate for treatment of preterm labor. Participants were 100 singleton pregnant women between 24 to 37 weeks of gestation with signs of preterm labor referred to Alzahra hospital in 2003. Exclusion criteria was maternal or fetal indications of pregnancy termination. After obtaining Consent letter, Women were divided in two groups: nifedipine and magnesium sulfate. Vital signs, vaginal bleeding, rupture of membranes, fetal heart rate, and uterine contractions were monitored.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2012062310089N1**

Registration date: **2013-06-07, 1392/03/17**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2013-06-07, 1392/03/17

Registrant information

Name

Roya Faraji Darkhaneh

Name of organization / entity

Guilan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 13 1322 5624

Email address

h_fertility@gums.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice Chancellor for Research, Guilan University of Medical Sciences

Expected recruitment start date

2003-03-03, 1381/12/12

Expected recruitment end date

2004-06-16, 1383/03/27

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison the effect of magnesium sulfate and nifedipine in the successful treatment of preterm labor

Public title

Magnesium sulfate and nifedipine on treatment of preterm labor

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Singleton pregnancy, 24 to 37 weeks of gestation, signs of preterm labor. Exclusion criteria : premature rupture of membrane, cervical dilatation > 4 cm, gestational age < 24 or >37 weeks, chorioamnionitis, vaginal bleeding, multiple pregnancy, previous cesarean section, previous uterus surgery, maternal or fetal indications for termination of pregnancy such as preeclampsia, fetal distress, fetal growth abnormalities and decreased blood pressure.

Age

From **15 years** old to **45 years** old

Gender

Female

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **100**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

This study is random

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethic Committee Vice Chancellor for Research of
Guilan University of Medical Sciences

Street address

Vice Chancellor for Research, Guilan University of
Medical Sciences, Namjo Street

City

Rasht

Postal code

Approval date

2003-03-03, 1381/12/12

Ethics committee reference number

336

Health conditions studied

1

Description of health condition studied

Preterm labor and delivery

ICD-10 code

O60.2

ICD-10 code description

Preterm spontaneous labor with term delivery

Primary outcomes

1

Description

Delaying delivery up to 48 hours

Timepoint

Every 15 minutes until stopping of uterine contractions

Method of measurement

Abdominal palpation of uterus

Secondary outcomes

1

Description

Cervical dilatation

Timepoint

Every 2 hours until stopping of uterine contractions

Method of measurement

Vaginal examination

2

Description

Uterine contractions

Timepoint

Every 15 minutes until stopping of uterine contractions

Method of measurement

Abdominal palpation of uterus

3

Description

Cervical effacement

Timepoint

Every 2 hours until stopping of uterine contractions

Method of measurement

Vaginal examination

4

Description

Fetal complications

Timepoint

During drug administration

Method of measurement

Physician assessment

5

Description

Maternal complications

Timepoint

During drug administration

Method of measurement

Physician assessment

Intervention groups

1

Description

Intravenous loading dose infusion was 4gr magnesium sulfate (20%) during 30 minutes, followed by a maintenance dose of 2 gr/hr until stopping or reducing uterine contractions. (magnesium sulfate heptahydrate 20% produced by Samen pharmaceutical company, Iran.)

Category

Treatment - Drugs

2

Description

We have used one capsule nifedipine (10 mg sublingual from Dana pharmaceutical company, Iran and its Generic name was Nifi-Gel). If uterine contractions persisted, we would use another capsule every 15 minutes; until a maximum dose of 40mg for one hour. Depending on tocolytic effects of nifedipine that we have used during one hour, we used a minimal dose of 60 mg every day. After 3 days, the dose would be decreased gradually and patient will receive 20 mg/day nifedipine up to 36 weeks of gestation.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Alzahra Hospital, Guilan University of Medical sciences

Full name of responsible person

Dr.Roya Faraji Darkhaneh

Street address

Namjo street, Alzahra Hospital

City

Rasht

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice Chancellor for Research, Guilan University of Medical Sciences

Full name of responsible person

Dr. Abdolrasol Sobhani

Street address

Vice Chancellor for Research, Guilan University of Medical Sciences, Namjo street

City

Rasht

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice Chancellor for Research, Guilan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Guilan University of Medical Sciences

Full name of responsible person

Dr.Roya Faraji Darkhaneh

Position

Associated Professor Guilan University of Medical Sciences

Other areas of specialty/work

Street address

Namjo street, Alzahra Hospital, Reproductive Health Research Center

City

Rasht

Postal code

Phone

+98 13 1322 5624

Fax

Email

royafaraji1371@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Guilan University of Medical Sciences

Full name of responsible person

Dr.Roya Faraji Darkhaneh

Position

Associated Professor of Obstetrics group, Guilan University of Medical Sciences

Other areas of specialty/work

Street address

Namjo street, Alzahra Hospital, Reproductive Health Research Center

City

Rasht

Postal code

Phone

+98 13 1322 5624

Fax

Email

royafaraji1371@yahoo.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Guilan University of Medical Sciences

Full name of responsible person

Seyedeh Fatemeh Dalil Heirati

Position

B.S.Midwifery

Other areas of specialty/work

Street address

Reproductive Health Research Center, Alzahra Hospital, Namjo Street

City

Rasht

Postal code**Phone**

00

Fax**Email****Web page address****Sharing plan****Deidentified Individual Participant Data Set (IPD)***empty***Study Protocol***empty***Statistical Analysis Plan***empty***Informed Consent Form***empty***Clinical Study Report***empty***Analytic Code***empty***Data Dictionary***empty*